ArticleCancer research communications2026
TNBC Spatial Transcriptomic Analysis across Clinical States Reveals Subtype-Specific Networks and Immunosuppressive Niches.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer is a heterogeneous disease composed of distinct molecular subtypes that influence prognosis and treatment response, with subtype discordance between primary and metastatic tumors contributing to therapeutic failure. Using GeoMx spatial transcriptomics, we profiled nonmetastatic primary tumors, metastatic primary tumors, and lymph node (LN) metastases to characterize transcriptional and immune-spatial changes during disease progression. Comparative analysis revealed strong tumor microenvironment reprogramming across clinical states. In stromal regions of metastatic tumors, we observed enrichment of extracellular matrix remodeling, tumor-associated macrophage activity, and epithelial-to-mesenchymal transition-related pathways. In epithelial compartments, nonmetastatic and LN tumors showed a secretory-proliferative program, whereas primary metastatic tumors were enriched for antigen presentation and interferon (IFN) signaling. Immune deconvolution demonstrated distinct immune landscapes, with nonmetastatic tumors enriched for innate immune cells, primary metastatic tumors showing increased T- and B-cell infiltration, and LN metastases exhibiting an immunosuppressive microenvironment dominated by M2-like macrophages and memory B cells (P < 0.05). Subtype analysis revealed frequent triple-negative breast cancer (TNBC) subtype switching during LN metastasis, with 70% of cases transitioning from nonbasal subtypes to unspecified or immunomodulatory subtypes, both associated with poorer prognosis (HR = 1.8; 95% CI, 1.2-2.9). Spatial immune profiling further identified "excluded" and "ignored" tumors lacking T-cell infiltration, whereas "inflamed" tumors retained active cytotoxic immune responses. Integrating molecular subtype, immune infiltration, and spatial architecture, we developed a novel framework termed immuno-spatial molecular subtypes (ISMS), which captures TNBC heterogeneity and immune-spatial plasticity across disease progression. SIGNIFICANCE: TNBC progression is poorly understood, particularly how tumor and immune ecosystems evolve. By applying spatial transcriptomics on tissues, we uncover that nonmetastatic tumors displayed metabolic programs and a more coordinated immune-proliferation balance. Metastatic primary showed stronger IFN and antigen-presentation programs, whereas LN metastases showed an immune-excluded niche. Our discovery that immune phenotypes diverge from canonical subtypes led to development of ISMS, a framework that captures TNBC plasticity more accurately than subtype alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.